Home The Action Management Committee Stefan Chlopicki (PL)

Thu,30Mar2017

Stefan Chlopicki

Professor, JCET Director
Jagiellonian Centre for Experimental Therapeutics (JCET),
Jagiellonian University,
Kraków, Poland
Tel.:+48126645464
Fax:+48122974615
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research interests

  • Experimental Pharmacology
  • Pathophysiology of endothelial dysfunction
  • Pharmacology of endothelium, ,
  • Role of endothelial and lipid mediators in inflammation, and in vascular biology
  • Pharmacology of platelets

Selected Recent Publications

  • Kostogrys RB, Franczyk-Zarow M, Maslak E, Gajda M, Mateuszuk L, Jackson CL, Chlopicki S: Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR(-/-)). Atherosclerosis 2012;223:327-331.
  • Csanyi G, Gajda M, Franczyk-Zarow M, Kostogrys R, Gwozdz P, Mateuszuk L, Sternak M, Wojcik L, Zalewska T, Walski M, Chlopicki S: Functional alterations in endothelial NO, PGI(2) and EDHF pathways in aorta in ApoE/LDLR(-)/(-) mice. Prostaglandins Other Lipid Mediat 2012;98:107-115.
  • Chlopicki S, Lomnicka M, Fedorowicz A, Grochal E, Kramkowski K, Mogielnicki A, Buczko W, Motterlini R: Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors. Naunyn Schmiedebergs Arch Pharmacol 2012;385:641-650.
  • Kramkowski K, Leszczynska A, Mogielnicki A, Chlopicki S, Fedorowicz A, Grochal E, Mann B, Brzoska T, Urano T, Motterlini R, Buczko W: Antithrombotic properties of water-soluble carbon monoxide-releasing molecules. Arterioscler Thromb Vasc Biol 2012;32:2149-2157
  • Mackiewicz U, Czarnowska E, Brudek M, Pajak B, Duda M, Emanuel K, Csanyi G, Fedorowicz A, Grochal E, Tyrankiewicz U, Skorka T, Mende U, Lewartowski B, Chlopicki S: Preserved cardiomyocyte function and altered desmin pattern in transgenic mouse model of dilated cardiomyopathy. J Mol Cell Cardiol 2012;52:978-987.

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.